VivoSeq
Musculoskeletal

Gout

34

Pipeline Programs↗

5

Active Trials↗

27

Companies Involved↗

Gout is a moderately active landscape with 34 programs across 27 companies. The most active players are Cerimon Pharmaceuticals, ANS Pharma, Kiniksa Pharmaceuticals (UK), Ltd.. 20 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

19/100

Mech. Concentration

21/100

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cerimon Pharmaceuticals

1 program

Phase 2A

ANS Pharma

1 program

Phase 2K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

4 programs

ApprovedTakeda logo

Takeda

2 programs

ApprovedC

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

82%

Small molecule

27 of 33 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody39%Protein / enzyme39%

Small molecule leads; the ring shows all 33 classified programs, each share of the total. Modality classified for 97% of 34 pipeline programs.

Analysis

Trial Status

32

clinical trials

Completed23 · 72%
Recruiting3 · 9%
Not yet recruiting2 · 6%
Terminated2 · 6%
Unknown status1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

32 trials

Tigulixostat (IBI128) vs Febuxostat in Gout
Recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 3·NCT07414394·600 enrolled
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Recruiting·CCrystalys Therapeutics·Phase 3·NCT07089875·500 enrolled
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Recruiting·MMassachusetts General Hospital·Phase 4·NCT04875702·650 enrolled
The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More
Not yet recruiting·SSeoul National University Hospital·Phase 4·NCT06622603·59 enrolled
The Impact of Initiating Dotinurad Urate-Lowering Therapy at Different Time Windows on Gout Flare Resolution Time: A Multicenter, Randomized, Parallel-Controlled Study
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Approved·NCT07661030·142 enrolled
Lesinurad and Febuxostat Combination Extension Study in Gout
Completed·AArdea Biosciences, Inc.·Phase 3·NCT01808144·196 enrolled
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Completed·Regeneron logoRegeneron·Phase 3·NCT00958438·248 enrolled
Study Utilizing Rilonacept in Gout Exacerbations
Completed·Regeneron logoRegeneron·Phase 3·NCT00855920·225 enrolled
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
Completed·MMochida Pharmaceutical Company, Ltd.·Phase 1·NCT03375632·26 enrolled
Long-Term Safety of Febuxostat in Subjects With Gout.
Completed·Takeda logoTakeda·Phase 2·NCT00174941·116 enrolled
Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients
Completed·LLG Chem·Phase 3·NCT05586958·354 enrolled
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
Completed·LLG Chem·Phase 3·NCT05586971·2,202 enrolled
RDEA3170 and Febuxostat Combination Study in Gout Subjects
Completed·AArdea Biosciences, Inc.·Phase 2·NCT02246673·64 enrolled
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
Completed·AArdea Biosciences, Inc.·Phase 2·NCT00741442·3 enrolled
Lesinurad and Allopurinol Combination Extension Study in Gout
Completed·AArdea Biosciences, Inc.·Phase 3·NCT01808131·717 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)